Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home News Equities

Astrana Health Q2 2024 Earnings Highlights: Strong Growth and Strategic Expansion

by Team Lumida
August 10, 2024
in Equities
Reading Time: 9 mins read
A A
0
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Astrana Health delivered robust Q2 2024 results, with 40% revenue growth and 34% adjusted EBITDA growth, while announcing significant strategic partnerships and acquisitions to expand its national footprint.

Summary

Astrana Health reported strong Q2 2024 financial performance, with total revenue increasing 40% to $486.3 million and adjusted EBITDA rising 34% to $47.9 million. The company’s Care Partners segment drove growth, contributing $463.3 million in revenue, up 44% year-over-year. CEO Brandon Sim emphasized the company’s strategic roadmap:

“We continue to execute at a high level, as the Astrana Health revenue grew to $486.3 million a 40% increase compared to the same period last year. And adjusted EBITDA rose to $47.9 million, a 34% increase year-over-year.”

Main Themes

  • Guidance: Raised bottom end of revenue guidance to $1.75 billion while maintaining top end at $1.85 billion; maintained full-year adjusted EBITDA outlook
  • Strategic Expansion: Announced partnerships with Anthem Blue Cross, Elation Health, and acquisition of Collaborative Health Systems (CHS)
  • Market Expansion: Entered new states including Arizona and Hawaii, with plans to serve over 1.1 million patients across 12 states by 2025
  • Value-Based Care: Increased full risk business to approximately 60% of total capitation revenue, up from 46% in the prior year
  • Utilization Trends: Reported stable utilization within expectations, with a slight uptick in inpatient utilization related to COVID-19 cases in California

Insights

Astrana Health’s strategic partnerships and acquisitions demonstrate a significant push for national expansion and diversification. The company’s ability to maintain profitability while rapidly growing suggests a scalable business model and effective integration capabilities.

Market Opportunity

Astrana Health is expanding its addressable market through strategic moves:

  • Entered Arizona through Care Partners segment, partnering with a primary care group serving over 50,000 patients
  • Partnered with Elation Health to access 32,000 clinicians nationwide for value-based care enablement
  • Acquired CHS, adding approximately 2,500 primary care providers and 100,000 senior members across multiple states

These expansions position Astrana to capitalize on the growing demand for value-based care across diverse geographic markets.

Market Commentary

The value-based care market continues to evolve, with Astrana Health positioning itself as a leader in care enablement and risk-bearing arrangements. The company’s focus on full risk contracts and technology-enabled care models aligns with industry trends towards more accountable and efficient healthcare delivery.

Customer Behaviors

Astrana Health is observing stable utilization trends across its Medicare Advantage, Managed Medicaid, and commercial books of business. The company noted:

“We are noticing a small uptick in inpatient utilization related to a surge in COVID-19 cases throughout California, but we believe, we remain within expectations in terms of current year guidance and we will continue to monitor the situation.”

This suggests that Astrana’s care management strategies are effectively managing patient behaviors and healthcare utilization.

Regulatory Policy

The acquisition of CHS requires regulatory approval, which is expected in the fourth quarter of 2024. This regulatory process is a key factor in the company’s expansion timeline and integration plans.

Economy Insights

While not providing extensive economic commentary, Astrana Health’s management noted that their utilization and cost trends remain within expectations, suggesting resilience to broader economic pressures affecting the healthcare industry.

Industry Insights

Astrana Health’s success in managing utilization and costs while expanding value-based care arrangements provides insights for other industry players:

  1. Technology-enabled care models can effectively manage costs and improve outcomes
  2. Multi-payer, multi-state strategies can drive growth in the value-based care sector
  3. Partnerships with electronic health record companies can accelerate the adoption of value-based care models

Key Metrics

Financial Metrics:

  • Revenue: $486.3 million (40% YoY increase)
  • Adjusted EBITDA: $47.9 million (34% YoY increase)
  • Net income: $19.2 million (46% YoY increase)
  • EPS (diluted): $0.40 (43% YoY increase)

KPIs:

  • Full risk business: ~60% of total capitation revenue (up from 46% YoY)
  • Managed lives: Over 1.1 million patients in value-based care arrangements expected by 2025
  • States served: Expansion from 3 to 12 states

Competitive Differentiators

  1. Proprietary technology and care enablement platform
  2. Ability to drive profitable growth while rapidly expanding
  3. Success in managing utilization and costs in value-based arrangements
  4. Strategic partnerships with payers and technology companies
  5. Scalable model for integrating acquisitions and new markets

Key Risks

  1. Integration challenges with rapid expansion and acquisitions
  2. Regulatory approval delays for the CHS acquisition
  3. Potential utilization spikes due to COVID-19 or other health events
  4. Execution risks in new markets and with new partnerships
  5. Competitive pressures in the value-based care market

Analyst Q&A Focus Areas

  • Utilization trends and cost management strategies
  • Details on the CHS acquisition and integration plans
  • Revenue and profitability expectations for new partnerships and markets
  • Strategy for converting partial risk to full risk arrangements
  • Capital allocation and M&A strategy

Astrana Health Summary:

Astrana Health’s Q2 2024 results demonstrate strong execution of its growth strategy, with significant revenue and EBITDA increases. The company’s expansion into new states, strategic partnerships, and the CHS acquisition position it for continued growth in the value-based care market. Key areas to watch include the successful integration of new acquisitions, regulatory approval for the CHS deal, and the company’s ability to maintain profitability while rapidly scaling across new markets. Astrana’s focus on technology-enabled care models and risk-bearing arrangements appears to be resonating in the market, potentially setting the stage for sustained long-term growth.

Tags: AstranaEARNINGS
Previous Post

Robinhood Markets, Inc. (HOOD) Q2 2024 Earnings Highlights: Record-Breaking Performance and Strategic Growth

Next Post

Harrow, Inc. Q2 2024 Earnings Highlights: Record Revenue and Strong Product Performance

Recommended For You

Musk Says Ousting Huang Was Like Kicking ‘Michael Jordan Off Your Team,’ Regrets Spending at Least $474 Million on the Midterms and Says Tesla Plans a Model Y With No Steering Wheel

by Team Lumida
1 hour ago
Elon Musk Reignites Legal Battle Against OpenAI and Sam Altman

At DealBook, Musk criticized Nvidia’s ousting of Jensen Huang, regretted his midterm spending and said Tesla is building a Model Y with no steering wheel.

Read more

Meta Pauses Its Class C Non-Voting Share Plan, and the $60 Billion Sale Tied to It, While a Pension Fund Lawsuit Heads to an April Trial in Delaware

by Team Lumida
1 hour ago
Meta’s Content Moderation Shift: Scale Trumps Twitter-Style Risks

Meta said it will not issue Class C non-voting shares while investors including CalSTRS pursue a lawsuit, delaying a planned $60 billion share sale.

Read more

Nadella Calls Microsoft’s Outlook Outage a ‘Perfect Storm’ Caused by a Latent Bug, Saying AI-Driven ‘Patch Velocity’ Is Destabilizing Old Systems, as the Stock Sits Nearly 9% Off Its Nov. 4 High

by Team Lumida
1 hour ago
Microsoft’s AI Empire: Nadella’s Bold Moves and Billion-Dollar Bets

Nadella said Microsoft should have tested before last week’s Outlook outage and warned AI-driven patching is creating instability in older systems.

Read more

Moody’s Cuts Nvidia’s Outlook to Stable From Positive on Governance Concerns After Huang’s Ouster, Saying an Upgrade of Its Aa1 Rating Is Unlikely for 12 to 18 Months

by Team Lumida
1 hour ago
The AI Capex Machine Keeps Roaring — Nvidia’s Manufacturing Partner Hon Hai Crushes Estimates as Server Demand Drowns Out Recession Fears

Moody’s lowered Nvidia’s outlook to stable from positive, saying Jensen Huang’s exit has added uncertainty to its strategy and financial policies.

Read more

Palo Alto Networks Jumps 7% After Raising Its Fiscal 2027 Outlook to as Much as $14.57 Billion and Agreeing to Buy AI Startup Applied Compute for $4.5 Billion in Stock

by Team Lumida
1 hour ago
Palo Alto Networks Earnings Highlights: Strong Q4 Performance and Strategic Platformization Success

Palo Alto beat estimates, lifted fiscal 2027 guidance and agreed to buy Applied Compute for $4.5 billion in stock, sending shares up more than 7%.

Read more

Anthropic Is Indicated 20% to 26% Above Its $83 IPO Price in Gray Markets, as IG Derivatives Point to a $1.35 Trillion Value and Hyperliquid Perps Trade Near $101

by Team Lumida
1 hour ago

Gray markets signal a 20% to 26% pop for Anthropic, with IG implying a $1.35 trillion value and Hyperliquid perpetuals near $101 before Thursday’s debut.

Read more

Anthropic Prices Its IPO at $83, Above the $70-$78 Range, Selling About 980 Million Shares to Raise $81.3 Billion in the Biggest Offering Ever

by Team Lumida
1 hour ago

Anthropic sold about 980 million shares at $83 to raise $81.3 billion, a record IPO valuing it near $1.5 trillion fully diluted ahead of its Nasdaq debut.

Read more

Costco’s US Comparable Sales May Grow More Than 10% in November as Tech Outages Spark Emergency Stockpiling, Mizuho Says, Raising Its Target to $1,150

by Team Lumida
17 hours ago

Mizuho said tech outages are driving panic buying at Costco, estimating late-October US comps ex-gas rose 11% to 12%, and lifted its target to $1,150.

Read more

Textron Sells Its Industrial Segment to Kingswood Capital for $1.2 Billion and Authorizes a 35 Million-Share Buyback to Focus on Aviation, Bell and Defense

by Team Lumida
17 hours ago

Textron agreed to sell its industrial unit for $1.2 billion, expects about $1.1 billion in net proceeds, and approved a new 35 million-share buyback.

Read more

Apple Trades at 37 Times Forward Earnings, Its Highest Since 2007, After a 30% Gain Makes It the Market’s AI Haven and a $5.1 Trillion Company

by Team Lumida
17 hours ago

Apple’s 30% gain this year has pushed it to 37 times forward earnings and a record PEG ratio, as investors pay up for a stock seen as an...

Read more
Next Post

Harrow, Inc. Q2 2024 Earnings Highlights: Record Revenue and Strong Product Performance

Bumble Inc. Q2 2024 Earnings Highlights: Strategic Reset Amid Growth Challenges

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

a close up of the front grill of a car

GM’s Gamble Pays Off as China Tightens Magnet Exports

October 13, 2025
Supreme Court Signals It Will Strike Down Trump’s Birthright Citizenship Order

Trump and the GOP Have $1 Billion in Cash for the Midterms — Democrats Have $261 Million

April 21, 2026
Target Surges Past Sales Slump; Macy’s Struggles to Keep Up

Target Corporation Q2, 2024 Earnings Highlights

August 22, 2024

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Investing Philosophy
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Investing Philosophy
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bank of America China Commercial Real Estate CPI data centers Donald Trump EARNINGS ELON MUSK Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Novo Nordisk Nuclear Energy Nvidia oil OpenAI private equity S&P 500 SEC Semiconductor stock market stock surge Tech Stocks tesla Trump Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018